PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
BETHESDA, Md., May 16, 2017 -- India Globalization Capital Inc. (NYSE MKT:IGC) announces that Craig Cheifetz, M.D. has joined the company as an advisor to provide guidance on clinical trials, biotechnology, neuroscience, immunology and microbiology.
Dr. Cheifetz is currently Regional Dean at Virginia Commonwealth University Inova Fairfax Campus and is the Medical Director of Inova VIP 360 (Northern Virginia's premier Concierge Medicine Program). Dr. Cheifetz received his M.D. from the State University of New York College at Buffalo and trained in Internal Medicine at Georgetown University. From 2011 to 2013, he served as the National GRMC Chairman.
“I welcome Dr. Cheifetz to the IGC advisory team and look forward to his contributions as we move forward in developing cannabis-based, combination therapies. We remain committed to accelerating our initiatives and building a robust portfolio of compounds to address large market conditions,” states Ram Mukunda, CEO of IGC.
About IGC
India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland.
For more information visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/
Forward-looking Statements
Please see forward-looking statements as discussed in detail in IGC's Form 10-K for fiscal year ended March 31, 2016, and in subsequent reports filed with the U.S. Securities and Exchange Commission.
Contact Info: Claudia Grimaldi 301-983-0998
